Arbutus Biopharma Corporation filed a Form 8-K with the Securities and Exchange Commission on August 21, 2026, announcing plans to launch a modified Dutch auction tender offer to repurchase up to US$230 million in value of its common shares.

Key Highlights

  • Tender Offer Size: Arbutus Biopharma plans to purchase up to US$230 million in value of its common shares.
  • Price Range: The offer price is set at between US$5.00 and US$5.75 per share.
  • Auction Structure: The offer is described as a modified "Dutch auction" tender offer.
  • Not Yet Commenced: According to the filing, the tender offer had not yet commenced as of the report date.
  • Regulatory Filings Pending: The company stated it will file a Schedule TO and related materials with the SEC and applicable Canadian securities regulatory authorities upon commencement.
  • Signed by CFO: The filing was signed by Tuan Nguyen, Chief Financial Officer of Arbutus Biopharma Corporation.

Arbutus Biopharma Announces Plan for Modified Dutch Auction Share Repurchase

Arbutus Biopharma Corporation (NASDAQ:ABUS), a biopharmaceutical company incorporated in British Columbia, Canada, and headquartered in Warminster, Pennsylvania, disclosed on August 21, 2026, that it issued a press release announcing its intention to launch a modified Dutch auction tender offer. Under this structure, the company would seek to repurchase up to US$230 million in value of its common shares at a price ranging from US$5.00 to US$5.75 per share, according to the filing.

The filing notes that the tender offer has not yet commenced and that "there can be no assurances that the Company will commence the tender offer on the terms described herein or at all." The company indicated that, upon commencement, it will file a tender offer statement on Schedule TO, including an offer to purchase, an accompanying issuer bid circular, and a letter of transmittal, with the SEC and applicable Canadian securities regulatory authorities. The filing further states that the tender offer will only be made pursuant to those materials once they are filed.

Arbutus Biopharma's common shares are registered under the ticker ABUS on the Nasdaq Stock Market LLC. The 8-K was filed under Item 8.01, covering Other Events, and was accompanied by a press release dated August 21, 2026, listed as Exhibit 99.1. The filing indicates shareholders should review the offer materials carefully when available, as they will contain the terms and conditions of the tender offer.

What Was Disclosed

Arbutus Biopharma Corporation filed an 8-K on August 21, 2026, disclosing plans for a modified Dutch auction tender offer to purchase up to US$230 million in common shares at US$5.00 to US$5.75 per share, with formal offer documents to follow upon commencement.